DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Linaclotide
Linaclotide
Peptide Therapeutics Designing a Science-Led Strategic Quality Control Program
Linaclotide: a Novel Therapy for Chronic Constipation and Constipation- Predominant Irritable Bowel Syndrome Brian E
Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
Chronic Constipation: an Evidence-Based Review
Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-Analysis of Licensed Therapies for Irritable Bowel Syndrome with Constipation
WHO Drug Information Vol
Systematic Literature Review and Indirect Treatment Comparison Of
2015.09 IBS Drug Class Review.Pdf
Draft Guidance on Linaclotide Active Ingredient
(12) United States Patent (10) Patent No.: US 9,708.371 B2 Kessler Et Al
ZELNORM™ (Tegaserod Maleate) for the Treatment of Irritable Bowel
208271Orig1s000
Effect of Laxatives and Pharmacological Therapies in Gut: First Published As 10.1136/Gut.2010.227132 on 4 January 2011
RISK ASSESSMENT and RISK MITIGATION REVIEW(S)
Efficacy of Drugs in Chronic Idiopathic Constipation: a Systematic Review and Network Meta-Analysis
Linzess® (Linaclotide), Trulance™ (Plecanatide) Prior Authorization Program Summary
Constipation – CIC/IBS-C/OIC NON-ONCOLOGY POLICY AMITIZA (Lubiprostone) LINZESS (Linaclotide) MOTEGRITY (Prucalopride) MOVANTI
Tenapanor: New Approach to Counter Irritable Bowel Syndrome with Constipation
Top View
Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
Chronic Constipation in Adults
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
Current Status of Selected Oral Peptide Technologies in Advanced Preclinical Development and in Clinical Trials TA Aguirre
LINZESS (Linaclotide) Capsules, for Oral Use Information for Instructions for Opening the Capsule and Initial U.S
Constipation and PD
Drugs for Constipation Month/Year of Review: March 2015 Purpose For
Tenapanor for Irritable Bowel Syndrome with Constipation NIHRIO (HSRIC) ID: 6704 NICE ID: 9736
Up-To-Date Diagnosis and Management of IBS and Chronic Constipation in Primary Care
(19) United States (12) Patent Application Publication (10) Pub
Comparative Efficacy of Linaclotide Versus Other Oral Constipation Treatments in Chronic Constipation: a Network Meta-Analysis
Constipation Pathway (Adults)
TARGETING CYCLIC GMP SIGNALING for the TREATMENT of GASTROINTESTINAL DISEASES by October COPYRIGHT© 2017 by Sarah Sharman
Linzess® (Linaclotide) Amitiza® (Lubiprostone)
Pharmacological Correction of Cystic Fibrosis Manifestations
Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
Changes Highlighted Final Version Date of Issue
Ibsrela (Tenapanor)
Amitiza® (Lubiprostone), Linzess® (Linaclotide) Prior Authorization Criteria Program Summary
Efficacy of Secretagogues in Patients with Irritable Bowel Syndrome with Constipation: Systematic Review and Network Meta-Analysis
Tenapanor Treatment of Patients with Constipation-Predominant Irritable Bowel Syndrome: a Phase 2, Randomized, Placebo-Controlled Effi Cacy and Safety Trial
WHO Drug Information Vol
Primary Care Laxative Prescribing in Adults
Clinical Pharmacology Biopharmaceutics Review(S)
Tenapanor (Ibsrela®) EOCCO POLICY
Linzess) Reference Number: CP.PMN.71 Effective Date: 11.01.15 Last Review Date: 11.20 Line of Business: HIM, Medicaid Revision Log
Guidelines for ATC Classification and DDD Assignment 2021
Irritable Bowel Syndrome and Constipation Agents
Treatment of Irritable Bowel Syndrome: a Review
Pharmacy Medical Necessity Guidelines: Gastrointestinal Medications
An Overview on Constipation and Liquid Paraffin for Its Treatment
Amitiza® (Lubiprostone) Capsules Linzess® (Linaclotide) Capsules Motegrity® (Prucalopride) Tablets Trulance® (Plecanatide) Tablets Effective 4/1/2020
Constipation – CIC/IBS-C/OIC AMITIZA (Lubiprostone) LINZESS
Constipation and Laxative Use in the Community
Linaclotide for Irritable Bowel Syndrome with Constipation
Guidelines for ATC Classification and DDD Assignment 2013
Magnesium Oxide in Constipation
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/PBIRG ANATOMICAL CLASSIFICATION
Management of Constipation in Adults (Updated September 2015)
Linaclotide (Linzess®) Classification: Gastrointestinal Agent—Guanylate Cyclase-C (GC-C) Agonist Pharmacology: Mechanism of A
Lwwus Mcg Jcg12793 21..28
Tegaserod (Zelnorm®) EOCCO POLICY
Linaclotide, Lubiprostone, Plecanatide, and Prucalopride
Interventional Study of the Efficacy and Tolerability of Linaclotide in the Treatment of Irritable Bowel Syndr
Contrasting Effects of Linaclotide and Lubiprostone